These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
815 related articles for article (PubMed ID: 7526027)
1. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027 [TBL] [Abstract][Full Text] [Related]
2. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952 [TBL] [Abstract][Full Text] [Related]
3. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576 [TBL] [Abstract][Full Text] [Related]
4. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group]. Reiter A; Schrappe M; Yakisan E; Sauter S; Henzler D; Zimmermann M; Graf N; Fengler R; Kühl J; Fleischhack G Klin Padiatr; 1994; 206(4):234-41. PubMed ID: 7967419 [TBL] [Abstract][Full Text] [Related]
5. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440 [TBL] [Abstract][Full Text] [Related]
6. [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Riehm H; Reiter A; Schrappe M; Berthold F; Dopfer R; Gerein V; Ludwig R; Ritter J; Stollmann B; Henze G Klin Padiatr; 1987; 199(3):151-60. PubMed ID: 3306129 [TBL] [Abstract][Full Text] [Related]
7. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL]. Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420 [TBL] [Abstract][Full Text] [Related]
8. [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991]. Zintl F; Malke H; Reimann M; Hermann J; Domula M; Dörffel W; Eggers G; Exadaktylos P; Hilgenfeld E; Kotte W Klin Padiatr; 1992; 204(4):221-9. PubMed ID: 1518257 [TBL] [Abstract][Full Text] [Related]
9. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M; Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546 [TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
14. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094 [TBL] [Abstract][Full Text] [Related]
16. [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas]. Sauerbrey A; Zintl F; Malke H; Reimann M; Maaser M; Domula M; Dörffel W; Eggers G; Exadaktylos P; Kotte W Klin Padiatr; 1993; 205(4):281-7. PubMed ID: 8377448 [TBL] [Abstract][Full Text] [Related]
17. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME; J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416 [TBL] [Abstract][Full Text] [Related]
19. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. Barredo JC; Devidas M; Lauer SJ; Billett A; Marymont M; Pullen J; Camitta B; Winick N; Carroll W; Ritchey AK J Clin Oncol; 2006 Jul; 24(19):3142-9. PubMed ID: 16809737 [TBL] [Abstract][Full Text] [Related]
20. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group]. Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]